Although phencyclidine and ketamine are used to model a hypoglutamate theory of schizophrenia, their selectivity for NMDA receptors has been questioned. To determine the affinities of phencyclidine, ketamine, dizocilpine and LSD for the functional high-affinity state of the dopamine D2 receptor, D2
While the clinical anti-dopaminergic actions of antipsychotic drugs are compatible with the hyperdopamine hypothesis of psychosis and schizophrenia, 1, 2 the psychoses caused by glutamate antagonists such as phencyclidine or ketamine suggest a hypo-glutamate component in psychosis. [3] [4] [5] However, phencyclidine also lowers plasma prolactin 6 and elicits rotation, 7 suggesting a direct or indirect dopaminemimetic action of phencyclidine.
Although phencyclidine and ketamine are not selective for glutamate NMDA receptors, 8 the precise affinities of these drugs for dopamine D2 receptors need to be clarified in order to determine their dopaminergic and non-dopaminergic components of action. More specifically, although phencyclidine had a dissociation constant of 37 000 nM at the D2 receptor in rat striatal homogenate, 8 phencyclidine had a dissociation constant of 1.3 nM for the functional high-affinity site of the cloned D2 receptor, or the D2 High receptor. 9 This apparent discrepancy may be resolved by the recent finding that dopamine itself has a dissociation constant of 3000 nM when competing vs [ 3 H]raclopride at striatal D2 receptors, but has a dissociation constant of 1.5 nM at the D2 High receptor when the link between dopamine D1 and D2 receptors is blocked by the D1 antagonist SCH23390. 10 The link between D1 and D2 receptors arises from several sources, including the colocalization of dopamine D1 and D2 receptors in at least 50% of the medium spiny neurons in the striatum, the cooperation and mutual potentiation of D1 and D2 agonists on various behaviors, and the biochemical conversion of D2 receptors from their functional high-affinity state, D2 High , into their low-affinity state, D2 Low , in the presence of a D1 antagonist. [10] [11] [12] [13] This D 1 -D 2 link has been detected in vitro in human and rat striata, 10, 11 and in tissue culture cells transfected with both D1 and D2, 12 but has not yet been demonstrated in humans by means of positron emission tomography and [
11 C]raclopride. However, in order to compare the potencies of psychotomimetics at dopamine D2 receptors with their potencies at NMDA receptors, it would be better to avoid using SCH23390. This is because SCH23390 can also affect the potency of drugs at the NMDA receptor, especially since it is known that D1 and NMDA receptors interact. [14] [15] [16] Although the blockade of D1 (by SCH23390) unmasks the functional D2 High states, 11 the addition of SCH23390 is only needed when using [
detects D2
High receptors without the addition of SCH23390. 17 Therefore, in order to obtain the potencies of phencyclidine, ketamine, dizocilpine and LSD at the functional D2
High receptor, the present study used [ 3 H]domperidone to label D2 receptors. The results indicate that the potencies of the psychotomimetics were greater at D2
High than at the NMDA receptor.
Materials and methods
We used the human cloned dopamine D2 Long receptor (in Chinese hamster ovary (CHO) cells 18 ) . The cells were harvested by gently scraping the cells off the bottom of the Petri dish, centrifuged, resuspended in phosphate-buffered saline (0.9% NaCl), recentrifuged and the pellet frozen at À701. When used, the frozen pellet was thawed, and the cells suspended at 200 mg protein/ml. The suspension was homogenized for 5 s (Brinkmann Polytron, setting 5 (maximum on scale was 10)), without any further washing or centrifugation.
Frozen rat brains were purchased (Pel-Freez, Rogers, AR, USA), partly thawed and the striata removed. To prepare the tissues for the drug/[ 3 H] ligand competition-type experiments, the striatal tissues were blotted and weighed; buffer was added (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl 2 , 4 mM MgCl 2 , with a final concentration of 120 mM NaCl added later in the final incubation tubes) to yield 4 mg tissue per ml. The suspension was homogenized with a glass-Teflon homogenizer (10 up-down strokes of a piston rotating at 500 rpm). The homogenate was not washed, centrifuged or preincubated because previous work found that these procedures resulted in a loss of 30 The tubes, containing a total volume of 1 ml, were incubated for 2 h at room temperature (201C), after which the incubates were filtered, using a 12-well cell harvester (Titertek, Skatron, Lier, Norway) and bufferpresoaked glass fiber filter mats (No. 7034, Skatron, Sterling, VA, USA). After filtering the incubate, the filter mat was rinsed with buffer for 15 s (7.5 ml buffer). The filters were pushed out and placed in scintillation minivials (Packard Instruments, Chicago, IL, USA). The minivials received 4 ml each of scintillant (Ready Solve, Beckman Co., CA, USA), and were monitored 6 h later for tritium in a Beckman L5000 scintillation spectrometer at 55% efficiency. 19 The competition data were analyzed as previously described; 20 the program provided two statistical criteria to judge whether a two-site fit was better than a one-site fit, or whether a three-site fit was better than a two-site fit.
The drug-induced incorporation of [
35 S]GTP-g-S (1250 Ci/mmol; final concentration 0.2-0.3 nM) was carried out using the procedure previously described. 8 17 Therefore, using the more readily displaceable [ In order to determine the functional concentration range for phencyclidine, the effect of phencyclidine on the incorporation of [
Results

Phencyclidine
35 S]GTP-g-S was tested on the human cloned D2 receptors. Phencyclidine at concentrations 2 nM or higher stimulated the incorporation of [ 35 S]GTP-g-S, with an EC 50% (relative effective concentration for 50% incorporation) of 90 nM, as shown in Figure 2 .
Ketamine
The data for ketamine were qualitatively similar to those for phencyclidine. For example, using Dopamine receptors, phencyclidine and ketamine P Seeman et al At the NMDA receptor, however, ketamine was less potent than at the D2 receptor, having a K i value of 31007300 nM (n ¼ 6) vs the binding of [ 3 H]dizocilpine (Figure 3 , bottom) to rat striatal tissue. The addition of 2 mM glutamate had no effect on the ketamine K i values.
Dizocilpine
The data for dizocilpine were also qualitatively similar to those for phencyclidine and ketamine, but dizocilpine was much more potent. Dizocilpine inhibited the binding of [ In order to confirm that dizocilpine was indeed recognizing a high-affinity site for D2, as suggested by the observation that dizocilpine inhibited the binding of [ Table 2 show that dopaminergic drugs, two antagonists and two agonists, inhibited the binding of [ 3 H]dizocilpine to the D2 Long receptors with the appropriate rank order characteristic of dopamine D2 receptor agonists, namely that n-propyl-norapomorphine is more potent than apomorphine.
The K d for [ 3 H]dizocilpine was 1.870.4 nM for the NMDA sites in the striatal tissue. The presence of 2 mM glutamate had no effect on the dizocilpine dissociation constants.
LSD-25
Using [ 3 H]domperidone, LSD-25 inhibited the binding at D2
High with a K i value of 270.3 nM (n ¼ 3) (Figure 5 , top) on human cloned D2 receptors. LSD-25 (up to 10 000 nM) had no effect on the binding of Figure 2 , because the data points overlap those for phencyclidine). The total absolute amount of LSDstimulated incorporation was 80% of that stimulated by dopamine.
Discussion
The data show that phencyclidine, ketamine, dizocilpine and LSD all have high affinities for the highaffinity state of dopamine D2 receptors, D2
High with dissociation constants of B3, 55, 0.3 and 2 nM, respectively (Table 1 ). High . This high-affinity state was eliminated in the presence of 200 mM guanilylimidodiphosphate. Total binding was B9000 dpm/filter; nonspecific binding in the presence of 10 mM S-sulpiride was B5000 dpm/filter. The present data are relevant to problems associated with testing the hypoglutamate theory of psychosis, because it has been proposed that dopamine abnormalities in psychosis are secondary to a primary hypofunction in glutamate neurotransmission. The hypoglutamate theory is supported by the fact that phencyclidine and ketamine are NMDA antagonists and elicit psychotic symptoms. 3, 4 The present findings illustrate, however, that phencyclidine and ketamine also act on the highaffinity state of dopamine D2 receptors with potent dissociation constants of 3 and 55 nM, respectively. These values compare with 313 and 3100 nM for phencyclidine and ketamine at NMDA receptors, respectively.
Moreover, the biphasic pattern of inhibition of [ 3 H]domperidone binding by phencyclidine and ketamine is compatible with agonist action at the dopamine D2
High state of the D2 receptors, considering that virtually all dopamine agonists have this biphasic pattern, in contrast to all dopamine antagonists, which reveal a monophasic pattern of ligand inhibition. 13, 17, 20 In addition, because receptor agonists accelerate the exchange of receptor-bound GDP for GTP, the stimulation of [ 35 High are invariably higher (B20-200 nM) and do not correspond to the dissociation constant of [ H]raclopride competition-type experiment, with a dopamine dissociation constant of 1.5 nM. Such a high-affinity state for D2 is not normally detected in striata, despite the fact that the high-affinity state of the dopamine D2 receptor is the physiologically functional state of the receptor in the anterior pituitary gland. 13 In fact, previous work found it difficult to detect high-affinity sites for dopamine D2 receptors in rat or human striatum in the presence of physiological concentrations of sodium ions, because these high-affinity sites were generally less than 5% of the population in 120 mM NaCl. 21 Thus, the determination of agonist dissociation constants at the high-affinity site of the D2 receptor was generally carried out in the absence of NaCl. 20 Considering that all three psychotomimetics, phencyclidine, ketamine and LSD, act on dopamine D2 and other receptors (such as serotonin receptors for LSD), these compounds are not sufficiently selective for testing theories of psychotomimetic action, as had been thought. 22 LSD is a known direct-acting partial agonist at dopamine D2 receptors, lowering the release of prolactin and stimulating rotation.
23,24 The Agonists N-propyl-norapomorphine-(À) 1 1 74 Apomorphine 5607100 SE for triplicate measurements. 23 Phencyclidine also stimulates dopamine receptors by a direct or indirect action, lowering the release of prolactin 25 and causing rotation. 6, 7 Although prolactin release from hemi-pituitary glands in vitro was not directly inhibited by 1 mM phencyclidine, 25 lower concentrations of phencyclidine need to be tested to determine whether phencyclidine can directly alter the release of prolactin release in vitro. This is because Pampillo et al 26 found that L-glutamate stimulates prolactin release via ionotropic glutamate receptors, but inhibits prolactin release via metabotropic glutamate receptors. It will be essential, therefore, to test the direct in vitro action of phencyclidine on the release of prolactin from cells in culture, using various methods to separate phencyclidine's actions on both the glutamate receptors and the dopamine D2 receptors. The analogue of phencyclidine, ketamine, directly reduces the basal release of prolactin. 27 Because the present data are entirely in vitro, they should not be confused or admixed with separate clinical data. Nevertheless, the present in vitro data are at least consistent with the clinical data on this topic. That is, the clinical agonist actions of phencyclidine and LSD in eliciting psychotic symptoms are selectively treated in the hospital emergency room by haloperidol and other dopamine D2-selective antagonists, 28, 29 supporting the idea that dopamine D2 receptors are the primary target for eliciting psychotic symptoms. Although it has been claimed that psychotic symptoms elicited by ketamine are not blocked by haloperidol, 3 Giannini et al 30 have found that 5 mg of intramuscular haloperidol caused significant reductions in psychotic symptoms. 31 It is important to note that the serum concentration of phencyclidine that elicits psychotomimetic action is between 10 and 50 nM. 32 This is precisely the active range of phencyclidine that directly acts on D2 High ( Figure 1 ) and stimulates D2 (Figure 2 ). In contrast, the NMDA receptor has phencyclidine K i values of 97 nM 34 and 124 nM 35 on rat brain membranes, and 196 nM 35 on the human cloned NMDA receptor (Table  1) .
A similar situation exists for ketamine, where the psychotomimetic concentration in the serum is of the order of 100-500 nM, 8 a value that matches the ketamine action (100-500 nM) at D2 High (Figure 3 , top), but not that at the NMDA receptor, which has a ketamine K i of 3100 nM for striatal tissue (Figure 3 , bottom), 760-2270 nM for brain membranes 33, 34 and 3150 nM 34 for cloned NMDA receptors ( Table 1 ). The data in Figure 4 show that dizocilpine recognized a high-affinity site for the D2 receptor at dizocilpine concentrations of 3-100 nM when competing vs the D2 ligand, [ 3 H]domperidone. As mentioned in Results, it was necessary to confirm the existence of this high-affinity site by using dopaminergic drugs to compete vs [ 3 H]dizocilpine. This was carried out for the data in Table 2 35 More important than the absolute K i values for NPA and apomorphine in Table 2 is the observation that the rank order of the agonists NPA and apomorphine was characteristic for typical dopamine D2 receptors, namely that NPA was more potent than apomorphine.
As discussed by Javitt and Zukin, 32 phencyclidine elicits a variety of behaviors in animals, including unique discrimination of phencyclidine, hyperactivity, stereotypy and tranquilization, the latter effect being especially pronounced in monkeys. While it is not possible to attribute each of these behaviors to single neurotransmitter systems, the pharmacology of phencyclidine-induced hyperlocomotion helps to clarify the role of dopamine. In particular, the work of Ö gren and Goldstein 36 has shown that three dopamine antagonists (haloperidol, raclopride and remoxipride) blocked locomotion elicited by low and high doses of phencyclidine. Because these three dopamine antagonists have very low affinity for the NMDA receptor, 37 with raclopride and remoxipride being highly selective for dopamine D2 receptors, 38, 39 dopamine must be an important component in the phencyclidine hypoglutamate model of schizophrenia.
In conclusion, with phencyclidine and ketamine having considerable potency at D2
High receptors, the use of these compounds as provoking agents in animals or humans actually tests a combined dopamine/glutamate theory of psychosis.
